Biography and Research Information
OverviewAI-generated summary
Renita Brown studies the development and efficacy of vaccines against SARS-CoV-2. Her research has investigated various vaccine platforms, including non-modified mRNA, Ad26.COV2.S, virus-like particles, and naked plasmid DNA vaccines. Studies have assessed vaccine protection against different SARS-CoV-2 variants, such as B.1.351 and B.1.1.7, in rhesus macaques. Brown's work also explores the impact of prior infection on protection against reinfection with emerging variants. Her collaborations include research with S. Alexandra Marshall, Andrew Simmons, Simon Chung, and Kaymon Neal, all at the University of Arkansas for Medical Sciences, with whom she has co-authored multiple publications. Brown's scholarship metrics include an h-index of 17, 45 total publications, and over 5,300 citations.
Metrics
- h-index: 17
- Publications: 44
- Citations: 5,343
Selected Publications
-
Assessing the perspectives of genetic counselors with oncology patients at the end of life (2025)
-
Mobile Health App for Adolescent Asthma Self-Management: Development and Usability Study of the Pulmonary Education and Knowledge Mobile Asthma Action Plan (2025)
Collaboration Network
Top Collaborators
- Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
- Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques
- Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques
- Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
- SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
Showing 5 of 14 shared publications
- Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
- Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques
- Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
- SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
- Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants
Showing 5 of 12 shared publications
- Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
- Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques
- Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
- SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
- Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants
Showing 5 of 12 shared publications
- Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
- Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques
- Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
- SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
- Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants
Showing 5 of 11 shared publications
- Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
- Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques
- Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
- SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
- Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants
Showing 5 of 10 shared publications
- Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
- Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques
- Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
- Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants
- Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates
Showing 5 of 10 shared publications
- Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
- Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques
- SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
- Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2
- Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates
Showing 5 of 10 shared publications
- Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
- Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques
- Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
- SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
- Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants
Showing 5 of 9 shared publications
- Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques
- Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
- SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
- Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants
- Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates
Showing 5 of 9 shared publications
- Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques
- SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
- Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates
- An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques
- A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates
Showing 5 of 8 shared publications
- Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques
- SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
- Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2
- Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates
- An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques
Showing 5 of 8 shared publications
- Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques
- SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
- Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates
- An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques
- A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates
Showing 5 of 8 shared publications
- Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
- Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques
- SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
- Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants
- A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates
Showing 5 of 7 shared publications
- Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques
- Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
- SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
- Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants
- Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates
Showing 5 of 7 shared publications
- Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques
- SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
- Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2
- Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates
- An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques
Showing 5 of 7 shared publications
Similar Researchers
Based on overlapping research topics